BidaskClub downgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a buy rating to a hold rating in a research report released on Wednesday morning, BidAskClub reports.

Other equities analysts have also recently issued reports about the stock. Goldman Sachs Group raised their target price on shares of Crispr Therapeutics from $52.00 to $75.00 and gave the company a neutral rating in a research note on Tuesday, November 19th. Canaccord Genuity raised their target price on shares of Crispr Therapeutics from $72.00 to $80.00 and gave the stock a positive rating in a report on Wednesday, November 20th. Roth Capital raised their target price on shares of Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Piper Jaffray Companies reiterated a buy rating and set a $104.00 price objective on shares of Crispr Therapeutics in a report on Monday, December 16th. Finally, Oppenheimer lifted their price objective on shares of Crispr Therapeutics from $65.00 to $80.00 and gave the company an outperform rating in a report on Monday, November 25th. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have given a buy rating to the company’s stock. The stock has an average rating of Buy and an average price target of $71.38.

Shares of NASDAQ CRSP opened at $59.44 on Wednesday. The firm’s 50 day moving average price is $65.98 and its 200-day moving average price is $51.14. Crispr Therapeutics has a 52-week low of $28.95 and a 52-week high of $74.00. The company has a current ratio of 8.32, a quick ratio of 8.32 and a debt-to-equity ratio of 0.06.

Crispr Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, October 28th. The company reported $2.40 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.95) by $3.35. Crispr Therapeutics had a negative net margin of 5.30% and a negative return on equity of 2.60%. The business had revenue of $211.93 million for the quarter, compared to the consensus estimate of $6.32 million. As a group, research analysts expect that Crispr Therapeutics will post 0.65 earnings per share for the current year.

In related news, President Rodger Novak sold 33,618 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Pablo J. Cagnoni sold 7,500 shares of Crispr Therapeutics stock in a transaction dated Tuesday, November 19th. The stock was sold at an average price of $62.00, for a total value of $465,000.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $465,000. The disclosure for this sale can be found here. In the last three months, insiders sold 56,118 shares of company stock valued at $3,620,760. 21.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $41,000. Aperio Group LLC purchased a new stake in shares of Crispr Therapeutics during the 2nd quarter worth about $153,000. Swiss National Bank grew its holdings in shares of Crispr Therapeutics by 28.6% during the 2nd quarter. Swiss National Bank now owns 48,600 shares of the company’s stock worth $2,289,000 after purchasing an additional 10,800 shares during the period. Wells Fargo & Company MN lifted its position in Crispr Therapeutics by 23.9% during the 2nd quarter. Wells Fargo & Company MN now owns 603,905 shares of the company’s stock worth $28,443,000 after acquiring an additional 116,540 shares in the last quarter. Finally, Trexquant Investment LP acquired a new position in Crispr Therapeutics during the 2nd quarter worth approximately $466,000. Institutional investors own 49.82% of the company’s stock.

About Crispr Therapeutics

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

See Also: Overbought

Analyst Recommendations for Crispr Therapeutics (NASDAQ:CRSP)



Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Source link